Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells

Molecular Therapy

Volumn 6, Issue 2, 2002, Pages 190-198

  Kaliberov, Sergey A ^a   Buchsbaum, Donald J ^a   Gillespie, G Yancey ^b   Curiel, David T ^c   Arafat, Waleed O ^c   Carpenter, Mark ^d   Stackhouse, Murray A ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c and Clinical Center   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; BAX; Lung cancer cells; Vascular endothelial growth factor

Indexed keywords

ADENOVIRUS VECTOR; CASPASE; GREEN FLUORESCENT PROTEIN; PROTEIN BAX; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; EPITHELIUM CELL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; LUNG CANCER; MULTIGENE FAMILY; PROMOTER REGION; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; BRONCHUS;

EID: 0036664443     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0648     Document Type: Article

References (45)

1. Reed, J. C. (2000). Mechanisms of apoptosis. Am. J. Pathol. 157: 1415-1430.
2. Adams, J., and Cory, S. (2001). Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 26: 61-66.
3. Adams, J., and Cory, S. (1998). The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326.
4. Gross, A., McDonnell, J., and Korsmeyer, S. (1999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13: 1899-1911.
5. Brambilla, E., et al. (1998). p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin. Cancer Res. 4: 1609-1618.
6. Apolinario, R. M., et al. (1997). Prognostic value of the expression of p53, Bcl-2, and Bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J. Clin. Oncol. 15: 2456-2466.
7. Chen, Y., et al. (1999). Expression of Bcl-2, Bax, and p53 proteins in carcinogenesis of squamous cell lung cancer. Anticancer Res. 19: 1351-1356.
8. Coll, J. L., et al. (1998). Antitumor activity of bax and p53 naked gene transfer in lung cancer: in vitro and in vivo analysis. Hum Gene Ther. 9: 2063-2074.
9. Benihoud, K., Yeh, P., and Perricaudet, M. (1999). Adenovirus vectors for gene delivery. Curr. Opin. Biotechnol. 10: 440-447.
10. Robbins, P. D., Tahara, H., and Ghivizzani, S. C. (1998). Viral vectors for gene therapy. Trends Biotechnol. 16: 35-40.
11. Kagawa, S., et al. (2000). Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res. 60: 1157-1161.
12. Xiang, J., et al. (2000). Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer. J. Gene Med. 2: 97-106.
13. Tai, Y. T., Strobel, T., Kufe, D., and Cannistra, S. A. (1999). In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res. 59: 2121-2126.
14. Lowe, S. L., et al. (2001). Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther. 8: 1363-1371.
15. Shinoura, N., et al. (2000). Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Ther. 7: 739-748.
16. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82: 4-6.
17. Arbisher, J. L., et al. (1997). Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA 94: 861-866.
18. Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., and Marme, D. (1995). Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270: 25915-25919.
19. Mukhopadhyay, D., Tsiokas, L., and Sukhatme V. P. (1995). Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55: 6161-6165.
20. Kieser, A., Weich, H. A., Brandner, G., Marme, D., and Kolch, W. (1994). Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963-969.
21. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845.
22. Mattern, J., Koomagi, R., and Volm, M. (1995). Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int. J. Oncol. 6: 1059-1062.
23. Andre, T., et al. (2000). Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int. J. Cancer 86: 174-181.
24. Brown, L. F., et al. (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 26: 86-91.
25. Miyagami, M., Tazoe, M., and Nakamura, S. (1998). Expression of vascular endothelial growth factor and p53 protein in association with neovascularization in human malignant gliomas. Brain Tumor Pathol. 15: 95-100.
26. Orre, M., and Rogers, P. A. (1999). VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int. J. Cancer 84: 101-108.
27. Suzuki, K., et al. (1996). Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 56: 3004-3009.
28. Yuan, A., et al. (2000). Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int. J. Cancer 89: 475-483.
29. Linderholm, B. K., et al. (2001). The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 61: 2256-2260.
30. Maeda, K., et al. (1996). Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863.
31. Van Engeland, M., Ramaekers, F. C., Schutte, B., and Reutelingsperger, C. P. (1996). A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 24: 131-139.
32. Koshikawa, N., Takenaga, K., Tagawa, M., and Sakiyama, S. (2000). Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 60: 2936-2941.
33. Varley, A. W., and Munford, R. S. (1998). Physiologically responsive gene therapy. Mol. Med. Today 4: 445-451.
34. Rak, J., et al. (1995). Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14: 263-277.
35. Forsythe, J. A., et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16: 4604-4613.
36. Shibata, T., Giaccia, A. J., and Brown, J. M. (2000). Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 7: 493-498.
37. Dachs, G. U., et al. (1997). Targeting gene expression to hypoxic tumor cells. Nat. Med. 3: 515-520.
38. Rampino, N., et al. (1997). Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969.
39. Yin, C., Knudson, C. M., Korsmeyer, S. J., and Van Dyke, T. (1997). Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637-640.
40. Miyashita, T., and Reed, J. C. (1995). Tumor suppressor p53 is a direct transcriptional activator of human Bax gene. Cell 80: 293-299.
41. Chow, N. H., et al. (1997). Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum. Pathol. 28: 698-703.
42. El-Assal, O. N., et al. (1998). Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 6: 1554-1562.
43. He, T. C., et al. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad Sci. USA 95: 2509-2514.
44. Graham, F. L., and van der Eb, A. J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology S2: 456-467.
45. SAS (1994). SAS/STAT User's Guide, version 6. SAS Institute Inc., Cary, N.C.